Navigation Links
Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference

RICHMOND, Calif., April 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 12:50 pm ET on Wednesday, May 1, 2013, at the 12th Annual Needham Healthcare Conference which will be held in New York.


The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
2. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
3. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
4. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
5. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
7. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
8. Sangamo BioSciences Reports First Quarter 2012 Financial Results
9. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:10/12/2015)... ... ... LifeTrak , a leader in consumer fitness, heart rate and activity ... tracker that seeks to meet the needs of multi-sport athletes. Zoom is the first ... both in water and on land, making it the only fitness tracker an athlete ...
(Date:10/10/2015)... 2015 Am 8. Oktober hat die ... für Kalifornien) ihre Würdigung der International Plasma Awareness ... Aufzeichnungen des Kongresses eintragen lassen. Die IPAW wird ... (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre Ziele bestehen ... über Plasmaspenden weltweit , Würdigung des Beitrages ...
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, ... biotechnology company developing next generation vaccines based on ... entered into an exclusive worldwide licensing agreement with ... treatment or prevention of any and all allergic ... Immunomic Therapeutics will receive an upfront payment of ...
(Date:10/9/2015)... ... October 09, 2015 , ... From blood to ... separating those cells from their surroundings for research, diagnostics, and cell therapy—also known ... address this, Ann Arbor-based startup Akadeum Life Sciences is developing a ...
Breaking Biology Technology:
(Date:10/8/2015)... 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet announces that revenues for the three months ... with $113,00 for the three months ended June ... September 30, 2015 were approximately $520,000. ...
(Date:10/6/2015)... Oct. 6, 2015 Track Group, Inc. (OTCQX: ... it has signed a contract with the Virginia Department ... full range of sentences under the Department,s oversight. ... Americas. "This contract with the Virginia DOC will expand ... and advances our position as a trusted leader in ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
Breaking Biology News(10 mins):